{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Passage Bio, Inc. technically bullish or bearish?
As of June 6, 2025, Passage Bio, Inc. shows a mildly bearish trend, driven by bearish daily moving averages and Bollinger Bands, despite a mildly bullish MACD on weekly and monthly charts.
Who are in the management team of Passage Bio, Inc.?
As of March 2022, the management team of Passage Bio, Inc. includes Dr. Tadataka Yamada (Independent Chairman), Dr. Bruce Goldsmith (CEO), Dr. Stephen Squinto (Acting Head of R&D), and several independent directors, bringing diverse expertise to the biotechnology sector.
What does Passage Bio, Inc. do?
Passage Bio, Inc. is a preclinical stage genetic medicines company focused on developing therapies for rare, monogenic central nervous system diseases. It has a market cap of $23.65 million and reported a net profit loss of $15 million as of March 2025.
How big is Passage Bio, Inc.?
As of Jun 18, Passage Bio, Inc. has a market capitalization of 23.65 million and reported net sales of 0.00 million with a net profit of -63.45 million for the latest four quarters. As of Dec 24, shareholder's funds were 61.26 million and total assets were 102.41 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
